Akorn Recalls Sulfacetamide Sodium Ophthalmic Solution Due to Sterility Concerns
Akorn, Inc. is recalling specific lots of Sulfacetamide Sodium Ophthalmic Solution because they failed antimicrobial effectiveness testing, raising concerns about sterility.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, and the hazard involves a lack of assurance of sterility in an ophthalmic product, which poses a significant risk of serious injury or infection.
Plain-English summary
Akorn, Inc. is recalling 57,920 bottles of Sulfacetamide Sodium Ophthalmic Solution, USP, 10%, Sterile, Rx Only, 15 mL bottles (NDC 17478-221-12). The recall involves three specific lots: Lot# 5A17A (Expiry 06/16), Lot# 5K21A (Expiry 03/17), and Lot# 6A08A (Expiry 06/17). The product was distributed nationwide and in Puerto Rico.
The recall was initiated due to a lack of assurance of sterility. Specifically, some lots failed Antimicrobial Effectiveness Testing on stability. This testing failure suggests that the preservative system may not be effective in maintaining the sterility of the product over time.
Consumers and healthcare providers should stop using the affected lots immediately. Patients should consult their healthcare provider for alternative treatment options. The recalling firm is Akorn, Inc., located in Lake Forest, IL.
The recalled product
- Product
- Sulfacetamide Sodium Ophthalmic Solution, USP, 10%, Sterile, Rx Only, 15 mL bottles, Mfd. by: Akorn, Inc., Lake Forest, IL 60045 --- NDC 17478-221-12
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Ophthalmic
- Affected units
- 57,920
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot# 5A17A
- Expiry 06/16 Lot# 5K21A
- Expiry 03/17 Lot# 6A08A
- Expiry 06/17
Distribution
Related recalls
Same manufacturer · Akorn, Inc.
See all →- HighGuaifenesin Oral Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighAkorn Hydromorphone Hydrochloride Injection Recalled Due to CGMP Deviations
FDA (Drugs) · 2023-06-07
- HighFDA Recalls Calcitriol Injection Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-06-07
- HighTobramycin Ophthalmic Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighMidazolam Injection Recalled Due to Manufacturing Compliance and Stability Study Issues
FDA (Drugs) · 2023-06-07
Same hazard · sterility failure
See all →- SevereROHTO DIGI-EYE Eye Drops Recalled Over Sterility Assurance Gap
FDA (Drugs) · 2026-07-29
- HighROHTO DRY-AID Eye Drops Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- SevereTransvenous Pacing Electrode Tray with Bipolar Balloon Pacing Electrode Recalled
FDA (Devices) · 2026-07-22
- SevereArterial Line Kit with Lidocaine HCL Injection Fails Sterility Testing
FDA (Devices) · 2026-07-22
- SevereOne-Piece Introducer Tray kits recalled for sterility failure
FDA (Devices) · 2026-07-22